June 4 (Reuters) - Novo Nordisk A/S:
* US FDA HAS APPROVED WEGOVY™ ( BRAND NAME FOR ONCE-WEEKLY SEMAGLUTIDE 2.4 MG INJECTION IN US) FOR CHRONIC WEIGHT MANAGEMENT
* EXPECTS TO LAUNCH WEGOVY(TM) IN UNITED STATES LATER IN JUNE 2021
* APPROVAL IS BASED ON RESULTS FROM STEP PHASE 3A CLINICAL TRIAL PROGRAMME Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.
